Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations
TD Clay, PA Russell, H Do, V Sundararajan, M Conron, GM Wright, A Dobrovic, MM Moore, SA McLachlan
Pathology | ELSEVIER SCIENCE BV | Published : 2016
Dr Clay declares previously receiving financial support to attend scientific meetings from Boehringer Ingelheim and Roche. All other authors state that they have no conflicts of interest to disclose.